Read Original Story

Costly New Prostate Cancer Drug Works In Mysterious Ways

Rating

5 Star

Costly New Prostate Cancer Drug Works In Mysterious Ways

Our Review Summary

The story had a primary focus of evaluating the evidence, raising some of the "mysterious ways" this drug works even in the headline.  And saying "It does work, sort of" – in the third paragraph.  But its strength is in how it educates readers about what confuses researchers about what they’ve seen, what it means, and how to explain it. Pithy quotes:  "It’s not a home run…this is not going to cure prostate cancer." Cutting to the core of the editorial writer’s issue: "The way the study was done, he says, ‘does not allow one to conclude’ that Provenge is working because it mobilizes the immune system specifically against prostate cancer." Writing that doesn’t beat around the bush:  "Deep in the data is further mystery…Nobody yet knows just how to explain these results." 

 

Why This Matters

Put this one on a shelf and pull it down anytime you need proof that journalists can scrutinize evidence (and get a 5-star score from us) in less than 500 words.  Show this to journalism students. 

Criteria

Does the story adequately discuss the costs of the intervention?

Satisfactory

The story itself only says "it’s pretty pricey."  But those words provide a hyperlink to another NPR story that discloses the drug cost as $93,000.  It would have taken the same amount of space to just state the cost in the current story.  Why make people click away to get the cost in another story?  Is the need to improve click rates driving this? Regardless, we’ll give the story the benefit of the doubt on this.  

Does the story adequately quantify the benefits of the treatment/test/product/procedure?

Satisfactory

In a broad overview comment, it’s sufficient for the story to have stated "men with prostate cancer that no longer responds to hormone therapy (basically, chemical castration) lived about four months longer if they took Provenge than if they got placebo treatment."

Does the story adequately explain/quantify the harms of the intervention?

Not Satisfactory

No discussion of any potential harms found in the studies.

Does the story seem to grasp the quality of the evidence?

Satisfactory

Excellent, understandable evaluation of the evidence.  Thorough.  Raises many important questions we haven’t seen in other stories. There are many angles one could take with the Provenge story.  For example, ABC News chose a cost angle (but in so doing, still injected a glowing personal anecdote, something the NPR story thankfully didn’t.)  Both of these angles are important.  But the cost angle is low-hanging fruit – an easy target.  Evaluating the evidence, as NPR did in this tight little story, can be difficult but is really important.  Big props!

Does the story commit disease-mongering?

Satisfactory

No disease-mongering.  The story makes it clear the drug was tested in men with prostate cancer who no longer respond to hormone therapy.

Does the story use independent sources and identify conflicts of interest?

Satisfactory

Solid quotes from the written editorial accompanying the study in the New England Journal of Medicine and even an appropriately cautious quote from the lead author of the study.

Does the story compare the new approach with existing alternatives?

Satisfactory

The story says the drug performed "better than the only other approved treatment for such advanced cancers" and that "Other immunotherapy approaches are in the pipeline, along with fancier versions of drugs to block the hormones that feed prostate cancer."

Does the story establish the availability of the treatment/test/product/procedure?

Satisfactory

The story is clear the drug was just approved by the FDA and that "Dendreon, the Seattle-based company that makes Provenge, says there’s a waiting list for the drug. The company estimates 100,000 American men have the kind of hormone-resistant, metastatic cancer the drug is approved to treat. But the company can only make enough at this point for 2,000 patients in the first year."

Does the story establish the true novelty of the approach?

Satisfactory

The story leads with: "After decades of dreaming about getting patients’ immune systems to fight cancer, immunotherapy is finally here." And later: "…after all, Provenge is just the first cancer immunotherapy on the market." 

Does the story appear to rely solely or largely on a news release?

Satisfactory

It’s clear this story didn’t rely on a news release.

Total Score: 9 of 10 Satisfactory

Comments

Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.